CN107735397A - Gpr55受体活性选择性调节剂:苯并吡喃吡唑衍生物 - Google Patents
Gpr55受体活性选择性调节剂:苯并吡喃吡唑衍生物 Download PDFInfo
- Publication number
- CN107735397A CN107735397A CN201680039783.1A CN201680039783A CN107735397A CN 107735397 A CN107735397 A CN 107735397A CN 201680039783 A CN201680039783 A CN 201680039783A CN 107735397 A CN107735397 A CN 107735397A
- Authority
- CN
- China
- Prior art keywords
- pyrazoles
- dihydro
- compound
- methoxyl group
- piperazinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Chromene pyrazole derivatives Chemical class 0.000 title claims abstract description 49
- 102100033061 G-protein coupled receptor 55 Human genes 0.000 title claims abstract description 39
- 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 106
- 239000000370 acceptor Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 208000004296 neuralgia Diseases 0.000 claims abstract description 6
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 6
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 5
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 5
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims abstract description 5
- 150000003217 pyrazoles Chemical class 0.000 claims description 90
- 125000004193 piperazinyl group Chemical group 0.000 claims description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 claims description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 14
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- VUNXBQRNMNVUMV-UHFFFAOYSA-N phenyl(piperazin-1-yl)methanone Chemical class C=1C=CC=CC=1C(=O)N1CCNCC1 VUNXBQRNMNVUMV-UHFFFAOYSA-N 0.000 claims description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 239000002585 base Substances 0.000 description 21
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 18
- 125000005999 2-bromoethyl group Chemical group 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ZUTQBIIKJALUQO-UHFFFAOYSA-N 2-methyl-2h-chromene Chemical compound C1=CC=C2C=CC(C)OC2=C1 ZUTQBIIKJALUQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000007445 Chromatographic isolation Methods 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229930003827 cannabinoid Natural products 0.000 description 3
- 239000003557 cannabinoid Substances 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940101165 GPR55 agonist Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- MZMOYVCDPQCUOP-UHFFFAOYSA-N piperazin-1-ium;2,2,2-trifluoroacetate Chemical compound C1C[NH2+]CCN1.[O-]C(=O)C(F)(F)F MZMOYVCDPQCUOP-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- ANEMDFCFHXKSHF-UHFFFAOYSA-N 1-piperazin-1-ylpentan-1-one Chemical compound CCCCC(=O)N1CCNCC1 ANEMDFCFHXKSHF-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- AIDLAEPHWROGFI-UHFFFAOYSA-N 2-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=C(C(O)=O)C=CC=C1C(O)=O AIDLAEPHWROGFI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 0 CC1(C)Oc(cc(cc2)OC)c2-c2n[n](CNC(CN(CC3)CCN3C3=CC(C)(*)C=CC=C3)=[U])cc12 Chemical compound CC1(C)Oc(cc(cc2)OC)c2-c2n[n](CNC(CN(CC3)CCN3C3=CC(C)(*)C=CC=C3)=[U])cc12 0.000 description 1
- XPHOXWMXDVPPHC-UHFFFAOYSA-N CC1(C)Oc2cc(OC)ccc2-c2c1cn[nH]2 Chemical compound CC1(C)Oc2cc(OC)ccc2-c2c1cn[nH]2 XPHOXWMXDVPPHC-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 229940093505 GPR55 antagonist Drugs 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical class CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JXNYEXCXLWTDLQ-UHFFFAOYSA-N O1NC=CC=C1.C(C1=CC=CC=C1)(=O)N1CCCCC1 Chemical class O1NC=CC=C1.C(C1=CC=CC=C1)(=O)N1CCCCC1 JXNYEXCXLWTDLQ-UHFFFAOYSA-N 0.000 description 1
- SYKLGFWZNOVZDI-UHFFFAOYSA-N OC1C(OC2=CC=CC=C2C1=O)=C Chemical class OC1C(OC2=CC=CC=C2C1=O)=C SYKLGFWZNOVZDI-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- WRLRISOTNFYPMU-UHFFFAOYSA-N [S].CC1=CC=CC=C1 Chemical compound [S].CC1=CC=CC=C1 WRLRISOTNFYPMU-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及式(I)的苯并吡喃吡唑衍生物家族:
Description
技术领域
本发明涉及药学领域。具体地,本发明涉及由7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑和7-甲氧基-4,4-二甲基-2,4-二氢苯并吡喃[4,3-c]吡唑衍生的哌嗪,其在制备药物中的用途,该药物用于治疗和/或预防与GPR55受体有关的失调的用途以及所述化合物用于与GPR55相关的药理学测定的用途。
背景技术
GPR55受体在1999年被克隆并首次鉴定。它是G蛋白偶联的跨膜受体。尽管它与CB1和CB2大麻素受体仅有14%的同源性,但它被提出是内源性大麻素系统的新成员。事实上,据发现,大麻素受体配体能够激活GPR55受体(GlaxoSmithKline WO0186305;AstraZenecaWO2004074844)。目前围绕着GPR55的药理学存在争议。今天,GPR55仍被认为是孤儿受体。然而,已报道内源性溶血磷脂酰肌醇(LPI)衍生物在过表达hGPR55的HEK293细胞中的ERK1/2磷酸化测定中刺激GPR55受体。迄今为止,GPR55受体特异性激动剂和/或拮抗剂非常少。一些苯甲酰哌嗪衍生物被鉴定为GPR55激动剂,其对CB1和CB2大麻素受体不产生作用。在hGPR55-U2OS细胞中使用β-抑制蛋白测定的高筛选药理学评估,鉴定了GPR55激动剂和选择性GPR55拮抗剂的几个家族,其后进行了分子建模研究。
已显示GPR55受体参与炎症性疼痛、神经性疼痛、代谢性疾病、骨发育和肿瘤细胞增殖的过程。因此,GPR55被认为是治疗GPR55相关疾病如糖尿病、帕金森病、多发性硬化症、神经性疼痛、骨质疏松症、胆管癌、乳腺癌、卵巢和前列腺癌、成胶质细胞瘤和皮肤癌的生物靶标。
本发明要求保护的化合物是基于苯并吡喃吡唑的结构。WO2010109050描述了苯并吡喃吡唑类化合物作为具有镇痛活性的大麻素。最近,在WO2014013117和P201430372中将苯并吡喃吡唑类描述为与大麻素活性有关的抗肿瘤药物。
发明内容
本发明公开了可用作用于验证GPR55受体的药理学工具和用作与GPR55相关的治疗剂的新化合物。本发明的新型化合物作用于GPR55受体。因此,它们可用于治疗GPR55受体相关的疾病和失调,如糖尿病、帕金森病、多发性硬化症、神经性疼痛、骨质疏松症、胆管癌、乳腺癌、卵巢癌和前列腺癌、成胶质细胞瘤和皮肤癌。
本发明的发明人已经发现,式(I)化合物选择性地作用于孤儿受体GPR55,因此可用于调节GPR55参与的过程。
本发明的一个方面涉及一种化合物,如通式(I)所示:
或其互变异构体、其药学上可接受的盐或其溶剂化物;其中:
·R1选自任选取代的芳基或-C(O)R3基团;R3选自芳基、杂环基、C1-C6烷基、C3-C6环烷基或-(CH2)n-O-芳基,其中n是选自1、2、3或4的值。
·R2为选自C1-C6亚烷基或-R4-C(O)-NH-R5-基,R4和R5为相同或不同的C1-C6亚烷基。
本发明的另一个方面涉及一种通式(II)的化合物:
或其互变异构体、其药学上可接受的盐或溶剂化物;其中R1和R2如上所定义。
本发明的另一个方面涉及一种通式(III)的化合物:
或其互变异构体、其药学上可接受的盐或溶剂化物;其中R1和R2如上所定义。
在一个优选的实施例中,R1是-C(O)R3基团,其中R3是任何上述可能的基团,尽管R3优选为芳基并且更优选为苯基。
在另一个优选的实施例中,R3是杂环基,更优选地R3选自呋喃基、噻吩基或四氢呋喃基。
在另一个优选的实施例中,R3是环己基。
在另一个优选的实施例中,R3是C1-C4烷基。
在另一个优选的实施方案中,R2是C1-C4亚烷基,更优选地为亚乙基。
根据一个优选的实施例中,式(I)的化合物选自下列:
-1-(2-(4-(2-呋喃甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-呋喃甲酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-苯甲酰基哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-苯甲酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(2-噻吩甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2-噻吩甲酰基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-苯氧基乙酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2-四氢呋喃基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-环己基羰基-哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-新戊酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
在另一个优选的实施例中,R1是任选取代的苯基。在更优选的实施中,R1为被C1-C4烷基或C1-C4烷氧基取代的苯基,更优选为被甲基或甲氧基所取代。
在另一个优选的实施例中,R2是-R4-C(O)-NH-R5-基团,R4和R5是相同或不同的C1-C4亚烷基。在更优选的实施例中,R4和R5是亚甲基。
根据一个优选的实施例中,式(II)的化合物选自下列:
-1-(2-(4-苯基哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-苯基哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(2-甲氧苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2-甲氧苯基)哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(2,3-二甲基苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2,3-二甲基苯基)哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(4-甲氧基苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
术语“烷基”在本发明中是指具有1至6个碳原子的饱和或不饱和的脂族链、直链、环化链或支链。例如但不限于,烷基可以是甲基、乙基、环己烷等。烷基可以被一个或多个取代基如卤素、羟基或羧酸任选取代。
在本发明中,术语“芳基”是指具有5至18个键的单个或多个芳族环,其中一个质子从环中去除。芳基例如但不限于苯基、萘基、二苯基、茚基、菲基或蒽基。芳基优选具有5至7个碳原子,更优选地,芳基为苯基。芳基自由基可以被一个或多个取代基任选取代,如(C1-C6)烷基、烷氧基、卤素、羟基或羧酸取代,更优选地,芳基被一个或两个甲氧基取代。
在本发明中,术语“环烷基”是指环状烃链自由基,优选具有3至6个碳原子,更优选6个,其为饱和或部分饱和并且仅由碳和氢原子组成,例如,环丙基、环戊基或环己基,并且其可被一个或多个基团如烷基、卤素、羟基、胺、酰胺、氰基等任选取代。
术语“杂环基”在本发明中是指含有1至4个选自氮、氧和硫的杂原子的环状结构。其结构可以是芳族的或氢化的。优选地,杂环基可以选自噻吩基、呋喃基、四氢呋喃基、吡啶基、咪唑基、吡唑基、吗啉基,但不限于此。杂环自由基可以被一个或多个取代基如(C1-C6)烷基、烷氧基、卤素、羟基或羧酸任选取代。
除非另有说明,本发明的化合物还涉及包括差异仅存在于一个或多个同位素富集的原子的化合物。例如,具有本发明结构,差异仅在于用氘或氚取代氢、或用13C或14C富集的碳取代碳、或富含15N的氮的化合物,都在本发明的范围内。
如本申请所用,术语“互变异构体”或“互变异构形式”是指可通过低能量障碍相互转换的不同能量的结构异构体。例如,质子互变异构体(也称为质子转移互变异构体)包括质子迁移(例如酮-烯醇或亚胺-烯胺异构化)引起的相互转换。价键互变异构体包括通过一些结合电子重排而相互转换。
术语“药学上可接受的盐或溶剂化物”是指任何药学上可接受的盐、酯、溶剂化物或任何其它化合物,其在给予接受者时能够(直接或间接)提供如本申请所述的化合物。然而,可以理解,药学上不可接受的盐也在本发明的范围内,因为它们可用于制备药学上可接受的盐。盐和衍生物的制备可以通过本领域已知的方法进行。
例如,本申请提供的化合物的药学上可接受的盐,由含有碱性部分或酸的原始化合物通过常规化学方法合成。通常,这些盐例如通过使化合物的酸或游离碱形式与化学计量的适当碱或酸在水或有机溶剂或两者的混合物中反应来制备。通常,非水介质如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈是优选的。酸加成盐的实例包括:无机酸加成盐,例如盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硝酸盐、磷酸盐;和有机酸加成盐,例如乙酸盐、马来酸盐、富马酸盐、柠檬酸盐、草酸盐、琥珀酸盐、酒石酸盐、苹果酸盐、扁桃酸盐、甲磺酸盐和对甲苯磺酸盐。碱加成盐的实例包括:无机盐,如钠、钾、钙、铵、镁、铝和锂盐;以及有机碱的盐,例如乙二胺、乙醇胺、N,N-二甲基乙醇胺、三乙醇胺、葡糖胺和碱性氨基酸的盐。
特别优选的衍生物,是对患者给药时,能提高本发明化合物的生物利用度(例如通过使口服给药的化合物更容易地被吸收到血液中)的化合物,或能增强原始化合物相对于其原始种类在生物区室(例如脑或淋巴系统)内的释放的化合物。
式(I)、(II)或(III)的化合物可以作为游离化合物呈结晶形式,或作为溶剂化物的形式,并且这两种形式都在本发明的范围内。溶剂化的方法在本领域中通常是已知的。合适的溶剂化物是药学上可接受的溶剂化物。在一个特定的实施例中,所述溶剂化物是水合物。
式(I)、式(II)和式(III)的化合物或其盐或溶剂化物,优选为药学上可接受的形式或基本上是纯的。药学上可接受的形式尤其意指除正常药物添加剂如稀释剂和载体之外,其具有药学上可接受的纯度水平,并且不含在正常剂量水平下被认为有毒的物质。活性成分的纯度优选高于50%,更优选高于70%,更优选高于90%。在一个优选的实施例中,其高于式(I)化合物或其盐的95%。
上面定义的式(I)、式(II)和式(III)化合物可以通过本领域已知的合成反应的组合获得,例如描述于文章Press JB,J.Heterocyclic Chem.,1985,22,561-564。
另一方面,本发明涉及式(I)、式(II)或式(III)化合物在制备药物中的用途。
另一方面,本发明涉及式(I)、式(II)或式(III)化合物在制备用于治疗和/或预防与GPR55受体有关的失调的药物的用途。
根据优选的实施例,与GPR55受体有关的失调选自糖尿病、帕金森病、多发性硬化症、神经性疼痛、骨质疏松症、胆管癌、乳腺癌、卵巢癌和前列腺癌、成胶质细胞瘤和皮肤癌。
另一方面,本发明涉及用于治疗和/或预防与大麻素受体相关失调的式(I)或式(II)或式(III)化合物。
本发明中使用的术语“失调”是指存在临床实践中可识别的行为或一组症状,其在大多数情况下伴随有不适或对个人习惯性活动的干扰。
因此,式(I)、式(II)或式(III)的化合物,其药学上可接受的盐或溶剂化物可用于预防和/或治疗需要调节GPR55受体的失调。含有治疗有效量的式(I)或式(II)化合物的药物组合物,其药学上可接受的盐或溶剂化物以及药学上可接受的赋形剂,构成本发明的又一方面。
对于式(I)、式(II)或式(III)化合物及其药学上可接受的盐或溶剂化物,其有效治疗的给药量,以及所述化合物用于治疗疾病状态的所述化合物的剂量,取决于许多因素,包括年龄、患者状况、疾病严重程度、给药途径和频率、使用的调节剂化合物等等。
另一方面,本发明还涉及用于对患者给药的药物组合物,其包含至少一种本发明化合物或其互变异构体、其药学上可接受的盐、其溶剂化物或其药物前体,以及药学上可接受的载体或载体、赋形剂或载体。
在一个优选实施例中,所述药物组合物进一步包括另外的活性成分。
所述药物组合物的一些实例是为口服给药、鼻腔给药、局部给药或胃肠外给药而制备的固体(片剂、丸剂、胶囊、颗粒状固体等)或液体(溶液、悬浮液或乳剂)。
在本发明的一个优选实施例中,所述药物组合物适于以固体或液体形式口服给药。可能的口服给药形式是片剂、胶囊剂、糖浆剂或溶液、并且可以含有制药领域已知的赋形剂、其作为粘合剂(例如糖浆、阿拉伯胶、明胶、山梨醇、黄蓍胶或聚乙烯吡咯烷酮)、填充剂(例如乳糖、糖、玉米淀粉、磷酸钙、山梨糖醇或甘氨酸)、崩解剂(例如淀粉、聚乙烯吡咯烷酮或微晶纤维素)或药学上可接受的表面活性剂如月桂基硫酸钠。
用于口服的组合物可以通过植物药学的常规方法以混合物和分散体的形式制备。片剂可以按照制药工业中已知的方法进行包衣。
所述药物组合物可以使用合适的剂量用作肠胃外给药,如作为本发明产品的无菌溶液、混悬液或冻干物。可以使用合适的赋形剂,例如pH缓冲剂或表面活性剂。
本发明的化合物或组合物的给药可以通过任何合适的方法来完成,例如静脉内输注和口服、腹膜内或静脉内途径。出于患者的方便性和待治疗疾病的慢性性质,口服给药是优选的。
本发明化合物的给药量取决于所选化合物的相对功效、待治疗疾病的严重程度和患者的体重。然而,本发明的化合物的给药为每天给药一次或多次,例如每日1、2、3或4次,总剂量为0.1-1000mg/kg/天。需要注意的是,剂量变化可能是必要的,取决于患者的年龄和状况、以及给药途径的变化。
本发明的化合物和组合物可以单独使用,或与其他药物组合使用以提供组合疗法。其他药物可以形成同一组合物的一部分,或提供为在相同时间或不同时间给药的单独组合物。
由于用本申请定义的所述化合物治疗的病理类型,组合治疗可能是特别有意义的,这些病理是特别复杂的,因为患者通常表现出症状以及各种损伤或改变的组合。因此,将几种药物组合起来可能是有意义的,每种药物都专门用于预防、减轻或治愈一种或几种特定的症状、损伤或改变,从而得到考虑到疾病或症状所涉及的许多、大部分或全部方面的针对该疾病或症状的全局形式组合治疗。
与本发明的化合物组合的药物可以是用于治疗任何疾病的已获得批准的或者是新开发的药物。
另一方面,本发明涉及式(I),式(II)或式(III)的化合物在制备与GPR55受体有关的生物测定中的试剂中的用途。
在本发明中,术语“试剂”是指添加到系统中以引起反应或检查反应是否发生的测试物质。
在本发明中,术语“生物测定”是指用于在活体或体外生物体中定量或定性测量物质的方法。定性测试用于确定物质在该生物体中的生理效应。定量测试用于通过测量该物质产生的生物反应来估计物质的浓度或效力。
本说明书和权利要求书中,术语“包括”及其变体不应理解为排除其他技术特征、添加剂、成分或步骤。对于本领域技术人员而言,本发明的其它目的、优点和特征从说明书部分和从本发明的实践是显而易见的。下面的实施例和附图仅提供作为说明,且并不意图限制本发明。
附图说明
图1.hGPR55-HEK293和HEK293细胞中的LPI浓度-响应曲线以及实施例2、6和8。数值表示为来自各重复两次的4个独立实验的平均值±SEM。所述数值对应于由LPI产生的最大刺激的百分比。
图2.在存在或不存在LPI时的实施例10在hGPR55-HEK293细胞中的浓度-响应曲线。数值表示为来自各重复两次的4个独立实验的平均值±SEM。所述数值对应于由LPI产生的最大刺激的百分比。
具体实施方式
现在将通过发明人进行的分析来说明本发明,其显示了本发明产品的有效性。
通用方法
反应产物的纯化通过使用硅胶60Merck 230-400目的柱层析进行。在由2767Sample Manager注射器/歧管模块、系统流体组织器分离模块、光电二极管阵列2998(UV-可见光)检测器和质谱仪3100质量检测器整合而成的Waters色谱仪上,通过半制备型高效液相色谱进行分离。使用SunFireTMC18反相色谱柱(19mm x 150mm)进行分离。所用固定相为:A(MeCN+0.1%甲酸)和B(H2O+0.1%甲酸)。70分钟内使用24mL min的流量执行梯度,并在λ=254nm监测。在具有正电喷雾源的Agilent Technologies 6520Accurate-MassQTOF LC/MS光谱仪上记录精确质谱。NMR分析在每种情况下指明的氘代溶剂中进行。在25℃下在Mercury 400(400和101MHz)或Varian 500(500和126MHz)光谱仪上记录13C-NMR,异核相关HMBC和HSQC。在MP70Mettler Toledo装置上测量熔点。
用于制备本发明式(I)化合物的起始产物是7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑。
为了合成7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑,将2-羟基-4-甲氧基苯乙酮用丙酮环化。用微波辐射使7-甲氧基-2,2-二甲基-2,3-二氢苯并吡喃-4-酮甲酰化得到3-羟基亚甲基苯并吡喃-4-酮。最后,与无水肼缩合,得到7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃并[4,3-c]吡唑。
制备7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑的合成路线总结于以下方案(I)中:
方案(I)
7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑的制备。
将3-(羟基亚甲基)-7-甲氧基-2,2-二甲基苯并二氢吡喃-4-酮(1.46g,6.27mmol)和在EtOH中的无水肼(0.58mL,83mmol)的溶液在60℃下搅拌2小时。在真空下蒸发溶剂后,通过硅胶中压色谱(己烷/AcOEt,1:1)纯化粗品。得到7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃并[4,3-c]吡唑(0.99g,69%),为白色固体。mp:158-160℃。MS(ES+,m/z)231[M+H]+。
A.制备式(III)的1-(2-(4-(2-酮)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑和式(I)的(2-(4-(2-酮)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑,其中R1是-C(O)-R3基团。
为了合成本发明的式(III)的1-(2-(4-(2-酮)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]和式(IV)的1-(2-(4-(2-酮)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑,用1,2-二溴乙烷将7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑烷基化。得到2个位置异构体,即1-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑和2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑,通过色谱分离。最后,与酰基哌嗪反应得到示例性的式(III)化合物和示例性式(IV)化合物。
下面的方案(II)总结了这个过程:
方案(II)
制备1-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑和2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃并[4,3-c]吡唑。
将NaH(28mg,1.19mmol)在无水THF中的悬浮液加入到在THF中的7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(0.23g,0.99mmol)。将混合物加热回流4小时。真空除去溶剂。用水洗涤溶于AcOEt中的粗制油状物,用MgSO4干燥,并在真空下蒸发溶剂。1-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑和2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑在硅胶(己烷/AcOEt,1:1)上进行色谱分离。
1-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(75mg,20%);1H NMR(400MHz,CDCl3)δ:7.34(d,J=7.9Hz,1H),7.22(s,1H),6.50(dd,J=7.9,2.4Hz,1H),6.43(d,J=2.4(T,J=6.6Hz),3.92(s,3H),1.45(s,6H)ppm;13C-NMR(101MHz,CDCl3)δ:161.7,155.3,144.7,133.4,123.9,121.9,108.5,103.4,101.8,76.7,59.3,55.8,29.6,28.5ppm;MS(ES+,m/z)337[M+H]+;HRMS C15H17BrN2O2:含量.336.0473,exp.336.0478.
2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(0.19g,51%);1H NMR(400MHz,CDCl3)δ:7.68(d,J=8.4Hz,1H),7.32(s,1H),6.63(dd,J=8.4,2.5Hz,1H),6.58(d,J=2.5Hz,1H),4.54(t,J=6.5Hz,2H),3.86(s,3H),3.80(t,J=6.5Hz,2H),1.66(s,6H)ppm;13C-NMR(101MHz,CDCl3)δ:161.1,154.7,143.8,124.6,123.2,120.9,110.9,108.1,103.2,76.6,55.5,53.8,30.7,29.4ppm;MS(ES+,m/z)337[M+H]+;HRMSC15H17BrN2O2:含量.336.0473,exp.336.0470.
实施例1-制备1-(2-(4-(2-呋喃甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑
将溶于THF中的1-(2-呋喃甲酰基)哌嗪(12mg,0.06mmol)和K2CO3(27mg,0.19mmol)在室温下搅拌10分钟。将1-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(22mg,0.06mmol)的THF溶液加入到混合物中,并加热回流过夜。真空除去溶剂。用水洗涤溶于EtOAc中的粗制油状物,用MgSO4干燥,过滤后蒸发溶剂。通过中压色谱分离1-(2-(4-(2-呋喃甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑(7mg,25%);1H-NMR(CDCl3)δ:7.57(d,J=8.5Hz),7.33-7.28(m,1H),7.11(s,1H),6.96-6.92(m,1H),6.60(dd,J=8.5)1H),6.39-6.36(m,1H),4.22(t,J=6.6Hz,2H),3.78(s,3H),3.39-3.21(m,4H),2.83(t,J=6.6Hz,2H),2.72-2.64(m,4H),1.52(s,6H)ppm;13C-NMR(101MHz,CDCl 3)δ:162.0,155.6,153.1,145.3,142.6,141.8,124.1,123.2,121.3,117.0,112.2,109.2,108.4,103.2,76.1,57.5,55.1,54.1,50.7,49.5,28.9ppm;MS(ES+,m/z)437[M+H]+;HRMS C24H28N4O4:含量.436.2110,exp.436.2107。
实施例2-制备2-(2-(4-(2-呋喃甲酰基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
使用(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(20mg,0.06mmol)和1-(2-呋喃甲酰基)哌嗪(11mg,0.06mmol)按照实施例1所述的步骤制备期望的化合物。黄色油状(6mg,24%);1H NMR(400MHz,CDCl3)δ:7.61(d,J=8.4Hz,1H),7.48-7.45(m,1H),7.18(s,1H),7.00-6.94(m,1H),6.54(dd,J=8.4,2.5Hz,1H),6.50(d,J=2.5Hz,1H),6.46-6.44(m,1H),4.23(t,J=6.5Hz,2H),3.76-3.62(s,7H),2.86(t,J=6.5Hz,2H),2.70-2.66(m,4H),1.58(s,6H)ppm;13C-NMR(101MHz,CDCl3)δ:160.9,159.3,154.5,148.0,143.9,142.9,124.2,123.1,121.0,116.7,111.5,111.2,108.0,103.2,76.7,58.0,55.5,53.6,51.3,50.4,29.5ppm;MS(ES+,m/z)437[M+H]+;HRMS C24H28N4O4:含量.436.2110,exp.436.2121。
实施例3-制备1-(2-(4-苯甲酰基-哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
使用(1-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(20mg,0.06mmol)和苯甲酰基哌嗪(11mg,0.06mmol)按照实施例1所述的步骤制备想要的化合物。黄色无定形固体(8mg,30%);1H-NMR(CDCl3)δ:7.55(d,J=8.4Hz,1H),7.38-7.29(m,5H),7.13(s,1H),6.49(dd,J=8.4,2.5Hz,1H),J=6.7Hz,2H),3.73(s,3H),3.41-3.26(m,4H),2.81(t,J=6.7Hz,2H)),2.59-2.37(m,4H),1.52ppm(s,6H);13C-NMR(101MHz,CDCl3)δ:170.3,165.1,160.7,154.3,130.2,129.7,128.5,127.1,124.4,123.9,122.8,107.9,107.6,103.0,76.4,57.8,55.4,55.3,53.6,50.1,29.2ppm;MS(ES+,m/z)447[M+H]+;HRMSC26H30N4O3:含量.446.2317,exp.446.2324。
实施例4-制备2-(2-(4-苯甲酰基-哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑
使用(2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(28mg,0.08mmol)和苯甲酰基哌嗪(16mg,0.08mmol)按照实施例1所述的步骤制备想要的化合物。黄色油状(30mg,81%);1H-NMR(400MHz,CDCl3)δ:7.62(d,J=8.4Hz,1H),7.46-7.32(m,5H),7.17(s,1H),6.55(dd,J=8.4,2.5Hz,J=6.6Hz,2H),3.79(s,3H),3.41-3.20(m,4H),2.87(t,J=6.6Hz,1H),6.50(d,Hz,2H),2.73-2.60(m,4H),1.58ppm(s,6H,OC(CH3)2);(CDCl3)δ:170.4(CO),160.8,154.5,142.9,135.8,129.9,128.6,127.1,124.1,123.0,120.9,111.1,107.9,103.1,76.6,57.9,55.4,53.7,50.2,47.9,29.4ppm;MS(ES+,m/z)447[M+H]+;HRMS C26H30N4O3:含量.446.2317,exp.446.2311。
实施例5-制备1-(2-(4-(2-噻吩甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
使用1-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(20mg,0.06mmol)和1-(2-噻吩甲酰基)哌嗪三氟乙酸(18mg,0.06mmol)按照实施例1所述的步骤制备想要的化合物。黄色无定形固体(6mg,23%);1H-NMR(400MHz,CDCl3)δ:7.49(d,J=8.8Hz,1H),7.44(dd,J=5.0,1.2Hz,1H),7.28(s,1H),7.23-7.21(m,6.54(d,J=2.6Hz,1H),4.54(t,J=7.1Hz,2H),7.03(dd,J=5.0,3.6Hz,1H),6.61-6.58(m,1H),6.57 3.82(s,3H),3.77-3.64(m,4H),2.93-2.87(m,2H),2.67-2.43(m,4H),1.58ppm(s,6H);13C-NMR(101MHz,CDCl3)δ:163.7,161.0,154.6,150.3,137.1,132.8,129.1,128.9,126.9,122.7,121.4,109.1,107.9,104.1,764,57.4,55.6,53.6,51.3,49.5,28.6ppm;MS(ES+,m/z)453[M+H]+;HRMS C24H28N4O3S:含量.452.1882,exp.452.1891。
实施例6-制备2-(2-(4-(2-噻吩甲酰基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
使用2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(30mg,0.09mmol)和1-(2-噻吩甲酰基)哌嗪三氟乙酸(28mg,0.09mmol)按照实施例1所述的步骤制备想要的化合物。黄色固体(22mg,55%);mp:163-165℃;1H-NMR(400MHz,CDCl3)δ:7.62(d,J=8.4Hz,1H),7.44(dd,J=5.0,1.2Hz,1H),7.25-7.23(m,1H),7.20(s,6.55(dd,J=8.4,2.5Hz,1H),6.51(d,J=2.5Hz,1H),4.27(t,J=6.5),7.03(dd,2H),3.79(s,3H),3.78-3.72(m,4H),3.01-2.91(m,2H),2.63-2.43(m,4H),1.59ppm(s,6H);13C-NMR(101MHz,CDCl3)δ:163.8,161.0,154.6,143.1,137.0,129.1,128.9,126.9,124.3,123.1,121.0,111.1,108.0,103.2,76.7,57.9,55.5,53.5,50.2,46.1,29.5ppm;MS(ES+,m/z)453[M+H]+;HRMS C24H28N4O3S:含量.452.1882,exp.452,1889。
实施例7:制备2-(2-(4-苯氧基乙酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑
使用2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(30mg,0.09mmol)和苯氧基乙酰基哌嗪(20mg,0.09mmol)按照实施例1所述的步骤制备想要的化合物。橙色固体(16mg,38%);mp:177-179℃;1H-NMR(500MHz,CD3OD)δ:7.56(d,J=8.5Hz,1H),7.52(s,1H),7.31-7.21(m,2H),7.00-6.90(m,3H),6.56(dd,J=8.5,2.5Hz,1H),6.48(d,J=2.5Hz,1H),4.76(s,2H),4.26(t,J=6.4Hz,2H),3.77(s,3H),3.63-3.50(m,4H),2.84(t,J=6.4Hz,2H),2.56-2.46(m,4H),1.56ppm(s,6H);13C-NMR(126MHz,CD3OD)δ:167.4,161.1,158.0,154.5,142.5,129.1,125.4,122.3,121.1,120.5,114.3,110.4,107.2,102.8,76.2,66.1,57.2,54.3,52.8,52.3,49.1,44.7,43.7,28.0ppm;MS(ES+,m/z)477[M+H]+;HRMS C27H32N4O4:含量.476.2423,exp.476,2427.
实施例8:制备2-(2-(4-(2-四氢呋喃甲酰基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
使用2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(30mg,0.09mmol)和四氢呋喃酰基哌嗪(16mg,0.09mmol)按照实施例1所述的步骤制备想要的化合物。黄色固体(14mg,36%);mp:158-160℃;1H-NMR(500MHz,CD3OD)δ:7.46(d,J=8.5Hz,1H),7.43(s,1H),6.46(dd,2.5Hz,1H),4.67-4.54(m,1H),4.17(t,J=6.5Hz,2H),3.83-3.81(m,1H),3.76-3.70(m,1H),3.68(s,3H)2H),2.46-2.33(m,4H),2.12-1.99(m,1H),1.95-1.86(m,1H),2.95(m,1H).1.85-1.75(m,2H),1.47ppm(s,6H);13C-NMR(126MHz,CD3OD)δ:171.3,161.1,154.5,142.5,125.4,122.3,120.5,110.4,107.2,102.8,76.2,75.2,68.7,57.2,54.3,52.9,52.3,47.5,44.9,43.7,28.8,28.0,25.1ppm;MS(ES+,m/z)441[M+H]+;HRMS C24H32N4O4:含量.440.2423,exp.440.2436.
实施例9:制备2-(2-(4-环己基羰基-哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑
使用2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(30mg,0.09mmol)和四氢呋喃酰基哌嗪(17mg,0.09mmol)按照实施例1所述的步骤制备想要的化合物。黄色固体(25mg,62%);mp:151-152℃;1H-NMR(400MHz,CDCl3)δ:7.63(d,J=8.5Hz,1H),7.18(s,1H),6.56(dd,J=8.5,2.5Hz,1H),6.51(d,J=2.4Hz,1H),4.23(t,J=6.6Hz,2H),3.79(s,3H),3.66-3.39(m,4H),2.85(t,J=6.6Hz,2H),2.54-2.35(m,4H),1.82-1.75(m,1H),1.73-1.61(m,4H),1.59(s,6H),1.57-1.42ppm(m,6H);13C-NMR(101MHz,CDCl3)δ:174.8,160.9,154.6,143.0,124.2,123.1,121.0,111.2,108.0,103.2,76.7,58.0,55.5,53.2,50.3,45.6,41.7,30.6,29.6,26.1ppm;MS(ES+,m/z)441[M+H]+;HRMSC26H36N4O3:含量.452.2787,exp.452.2773。
实施例10-制备2-(2-(4-新戊酰基-哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
使用2-(2-溴乙基)-7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(20mg,0.06mmol)和新戊酰基哌嗪(10mg,0.09mmol)按照实施例1所述的步骤制备想要的化合物。黄色无定形固体(8mg,32%);1H-NMR(400MHz,CDCl3)δ:7.62(d,J=8.4Hz,1H),7.18(s,1H),6.55(dd,J=8.4,2.5Hz,1H),6.51(d,J=J=6.6Hz,2H),3.79(s,3H),3.63(t,J=5.0Hz,4H),2.84(t,J=(t,J=5.0Hz,4H),1.59(s,6H),1.26(s,9H)ppm;13C-NMR(101MHz,CDCl3)δ:176.5,160.9,154.6,142.9,124.2,123.1,121.0,111.2,108.0,103.2,76.7,58.0,55.5,53.6,50.2,45.3,38.8,29.5,28.6ppm.MS(ES+,m/z)427[M+H]+;HRMS C24H34N4O3:含量.426.2630,exp.426.2618.
B.制备式(V)的1-(2-(4-芳基哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑和式(I)的2-(2-(4-芳基哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑,其中R1是芳基。
对于合成1-(2-(4-芳基哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑和式(I)的2-(2-4-芳基哌嗪基)乙酰胺基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑,其中R1为芳基,用相应的N-羟甲基-2-(4-苯基哌嗪基)乙酰胺将7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑烷基化。
下面的方案(III)总结了这个过程:
方案(III)
通过用苯基哌嗪和相应的2-氯-N-羟甲基乙酰胺进行N-烷基化来制备N-羟甲基-2-(4-苯基哌嗪基)乙酰胺。
下面的方案(IV)总结了这个过程:
方案(IV)
制备N-羟甲基-2-(4-苯基哌嗪基)乙酰胺
将2-氯-N-羟甲基乙酰胺(2当量)的乙腈溶液加入到相应的苯基哌嗪(1当量)与K2CO3(1.5当量)在乙腈中的混合物中。将混合物加热回流2-5小时。真空除去溶剂。用水洗涤溶于AcOEt中的粗制油状物,用MgSO4干燥,并在真空下蒸发溶剂。硅胶快速层析(EtOAc)得到相应的N-羟甲基-2-(4-苯基哌嗪基)乙酰胺。
N-羟甲基-2-(4-苯基哌嗪基)乙酰胺(41%)。mp:112-114℃;1H-NMR(400MHz,CDCl3)δ:8.10-8.02(brs,1H),7.39-7.22(m,2H),7.06-6.85(m,3H),4.82(s,2H),3.28-3.19(m,4H),3.13(s,2H),2.90-2.57ppm(m,4H);13C-NMR(101MHz,CDCl3)δ:173.6,151.5,129.8,129.7,120.5,119.3,116.7,73.1,62.0,54.1,53.7,50.9,49.8ppm;MS(ES+,m/z)250[M+H]+;Anal.C13H19N3O2:含量.C 62.63%,H 7.68%,exp.C62.41%,H 7.83%.
N-羟甲基-2-(4-(2-甲氧基苯基)哌嗪基)乙酰胺(63%)。mp:134-136℃;1H-NMR(400MHz,CDCl3)δ:8.14-8.11(br s,1H),7.03-6.96(m,2H),6.89-6.78(m,2H),4.79(s,2H),3.94-3.64(m,5H),3.17-2.89(m,4H),2.84-2.66ppm(m,4H);13C-NMR(101MHz,CDCl3)δ:171.4,151.7,140.4,122.6,120.5,117.6and 110.8,63.0,61.0,54.8,53.6,53.2,51.0,50.1ppm;MS(ES+,m/z)280[M+H]+;Anal.C14H21N3O3:含量.C 60.20%,H 7.58%,Found:C60.31%,H 7.72%.
N-羟甲基-2-(4-(2,3-二甲基苯基)哌嗪基)乙酰胺(25%)。mp:126-127℃;1H NMR(400MHz,CDCl3)δ:8.19-8.14(brs,1H),7.07(t,J=7.6Hz,1H),6.98-6.90(m,2H),5.59-5.57(br s,1H 2H),2.94-2.92(m,4H),2.77-2.73(m,4H),2.27(s,3H),2.21(s,3H),2.21(s,2H)ppm;13C-NMR(101MHz,CDCl3)δ:173.8,172.0,151.2,138.0,131.3,125.8,125.1,74.6,67.3,63.7,61.5,54.1,52.2,20.6,13.9ppm;MS(ES+,m/z)278[M+H]+;Anal.C15H23N3O2:含量.C 64.96%,H 8.36%,Found:C 65.09%,H 8.03%.
N-羟甲基-2-(4-(4-甲氧基苯基)哌嗪基)乙酰胺(24%)。mp:140-143℃;1H-NMR(400MHz,CDCl3)δ:7.09-6.95(m,2H),6.71-6.54(m,2H),4.83(s,2H),3.78-3.60(m,5H),3.14-3.05,4H),2.77-2.71ppm(m,4H);13C-NMR(101MHz,CDCl3)δ:173.0,152.4,143.6,123.4,122.1,118.6,112.3,65.7,63.2,55.1,54.3,53.8,51.8,51.2ppm;MS(ES+,m/z)280[M+H]+;Anal.C14H21N3O3:含量.C 60.20%,H 7.58%,exp.C60.56%,H 7.25%.
制备式(V)的1-(2-(4-芳基哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑和式(IV)的2-(2-(4-芳基哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑的一般过程。
在0°和氮气氛下将7-甲氧基-4,4-二甲基-1,4-二氢苯并吡喃[4,3-c]吡唑(1当量)的无水THF溶液缓慢加入到NaH(3当量)的无水THF悬浮液中。10分钟后,在室温下搅拌的同时加入相应的N-羟甲基-2-(4-苯基哌嗪基)乙酰胺(2当量)。将反应混合物加热回流12-72小时。真空除去溶剂。用水洗涤溶于AcOEt中的粗制油状物,用MgSO4干燥,并在真空下蒸发溶剂。在C18-二氧化硅(CH3CN/H2O)上进行半制备型色谱分离,得到1-(2-(4-芳基哌嗪基)乙酰胺基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑和相应的2-(2-(4-芳基哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
实施例11.制备1-(2-(4-苯基哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑
根据上述制备的一般方式制备所需的化合物。
白色固体(13%).mp:196-198℃;1H-NMR(500MHz,CDCl3)δ:8.02-7.97(brt,J=6.3Hz,1H),7.76(d,J=8.7Hz,1H),7.26(s,1H),6.85-6.74,6.55(dd,J=8.6,2.6Hz,2H),6.53-6.46(m,2H),6.45(d,J=2.5Hz,1H),5.73(d,J=6.3Hz,2H),3.71(s,3H),3.13-3.07(m,4H),3.03(s,2H),2.57-2.48(m,4H),1.52(s,6H)ppm;13C-NMR(126MHz,CDCl3)δ:170.2,165.1,161.0,154.3,149.2,133.8,132.5,129.1,123.3,121.4,120.0,116.2,107.8,103.85,76.73,61.3,55.3,54.32,53.4,49.1,28.24ppm;MS(ES+,m/z)462[M+H]+;HRMSC26H31N5O3:含量.461.2426,exp.461,2433.
实施例12.制备2-(2-(4-苯基哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑
根据上述制备的一般方式制备所需的化合物。
无定形固体(5%);1H-NMR(500MHz,CD3OD)δ:8.44-8.40(br s,1H),7.51(d,J=8.5,1H),7.44(s,1H),7.15-7.04(m,2H),6.82((d,J=7.4,1.0Hz,1H),6.47(dd,J=8.5,2.4Hz,1H),6.39(d,J=2.4Hz,1H)(M,4H),3.02(s,2H),2.55-2.49(m,4H),1.46(s,6H)ppm;13C-NMR(126MHz,CD3OD)δ:173.7,162.7,156.1,152.7,144.6,130.0,126.6,123.9,122.4,121.1,117.5,111.5,108.8,104.2,77.6,62.1,55.8,55.4,54.3,54.2,50.5,50.4,29.3ppm;MS(ES+,m/z)462[M+H]+;HRMS C26H31N5O3:含量.461.2426,exp.461,2421.
实施例13.制备1-(2-(4-(2-甲氧基苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
根据上述制备的一般方式制备所需的化合物。
白色无定形固体(3%);1H-NMR(500MHz,CDCl3)δ:7.35(d,J=8.1Hz,1H),7.16(s,1H),6.71-6.59(m,4H),6.42(dd,J=8.1,2.4Hz,2H),3.59(s,3H),3.54(s,3H),3.29(s,2H),3.10-3.03(m,4H)),2.98-2.86(m,4H),1.69(s,6H)ppm;13C-NMR(126MHz,CDCl3)δ:175.0,160.4,155.6,155.1,149.5,147.1,130.2,127.5,124.9,118.7,116.9,116.3,113.3,111.4,106.8,104.2,75.8,61.4,55.9,55.1,54.0,53.7,51.3,25.9ppm;MS(ES+,m/z)492[M+H]+;HRMS C27H33N5O4:含量.491.2532,exp.491,2528.
实施例14.制备2-(2-(4-(2-甲氧基苯基)哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
根据上述制备的一般方式制备所需的化合物。
黄色油状(8%);1H-NMR(500MHz,CDCl3)δ:7.04(d,J=7.5Hz,1H),6.91(s,1H),6.69-6.51(m,5H),6.42(d,J=2.6Hz,1H),3.64(s,3H),3.59(s,3H),3.16(s,2H),2.92-2.89(m,4H),2.76-2.70(m,4H),1.54(s,6H)ppm;13C-NMR(126MHz,CDCl3)δ:173.2,163.1,156.7,153.1,148.1,144.9,132.6,126.1,125.6,120.9,118.2,117.5,114.0,110.6,109.4,106.0,75.3,60.2,56.8,56.1,54.6,52.5,50.7,26.4ppm;MS(ES+,m/z)492[M+H]+;HRMS C27H33N5O4:含量.491.2532,exp.491,2540.
实施例15:制备1-(2-(4-(2,3-二甲基苯基)哌嗪基)乙酰氨基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
根据上述制备的一般方式制备所需的化合物。
黄色油状(2%);1H-NMR(500MHz,CDCl3)δ:8.08-8.02(brt,J=6.4Hz,1H),7.76(d,J=8.1Hz,1H),7.50(s,1H),6.94(t,J=(D,J=7.7Hz,1H),6.61(dd,J=8.1,2.6Hz,1H),6.48(d,J=7.5Hz,2.6Hz,1H),5.61(d,J=6.4Hz,2H),3.84(s,3H),3.08(s,2H),2.77-2.69(m,4H),2.64-2.59(m,4H),2.31(s,3H),2.27(s,3H),1.48(s,6H)ppm;13C-NMR(126MHz,CDCl3)δ:169.8,162.4,156.0,151.3,144.2,140.3,132.5,126.1,125.0,123.9,123.1,121.8,117.2,109.8,108.4,104.9,75.7,61.3,56.0,54.7,53.3,51.9,28.8,19.7,14.1ppmMS(ES+,m/z)490[M+H]+;HRMS C28H35N5O3:含量.489.2739,exp.489.2746.
实施例16.制备2-(2-(4-(2,3-二甲基苯基)哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
根据上述制备的一般方式制备所需的化合物。
白色固体(4%).mp:199-201℃;1H-NMR(500MHz,CDCl3)δ:8.22-8.17(brt,J=6.9Hz,1H),7.62(d,J=8.5Hz,1H),7.42(s,1H),7.08(t,J=1H),6.87(d,J=7.7Hz,1H),6.57(dd,J=8.5,2.5Hz,1H),6.51(d,J=2.5Hz,1H),5.54(d,J=6.9Hz,2H),3.79(s,3H),3.11(s,2H),2.87(t,J=4.8Hz,4H),2.63(t,J=4.8Hz,4H),2.25(s,3H),2.18(s,3H),1.58(s,6H)ppm;13C-NMR(126MHz,CDCl3)δ:171.5,161.0,154.6,151.1,143.5,138.0,131.2,125.8,125.2,124.7,122.8,121.5,116.6,110.4,108.0,103.0,76.5,61.4,55.3,54.2,53.9,52.0,29.1,20.6,13.8ppm;MS(ES+,m/z)490[M+H]+;HRMS C28H35N5O3:含量.489.2739,exp.489.2750.
实施例17.制备1-(2-(4-(4-甲氧基苯基)哌嗪基)乙酰氨基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
根据上述制备的一般方式制备所需的化合物。
黄色油状(14%);1H-NMR(500MHz,CDCl3)δ:7.50-7.48(brt,J=5.1Hz,1H),6.81-6.76(m,4H),6.76-6.68(m,2H),6.47(dd,J=5.1Hz,2H),3.68(s,3H),3.63(s,3H),3.01(s,2H),2.97-2.94(m,4H),2.55-2.47(m,4H),1.46(s,6H)ppm;13C-NMR(126MHz,CDCl3)δ:172.2,161.2,154.6,154.2,145.2,143.2,125.1,122.4,120.9,118.7,113.8,110.0,107.3,102.7,76.1,60.6,54.4,54.3,53.9,52.9 50.4,27.8ppm;MS(ES+,m/z)492[M+H]+;HRMS C27H33N5O4:含量.491.2532,exp.491.2524.
C.生物测定
在本发明中,通过用实时细胞阻抗测量(xCELLigence实验)进行体外测定来评估本发明化合物对GPR55受体的活性。这些测定在稳定形式的过表达重组GPR55受体的HEK293人胚胎肾细胞系(hGPR55-HEK293)上进行。在用本发明的示例性化合物进行刺激的前一天接种细胞。
GPR55激动剂活性。激动剂化合物对GPR55受体的激活产生了被系统检测到的细胞阻抗,并与溶血磷脂酰肌醇(LPI)(参考GPR55配体)进行比较。将在1μM浓度下测量的LPI效应设定为100%。在加入本发明的实施例化合物5分钟后观察到最大响应。因此,在此时确定了剂量-响应曲线。在添加本发明待评估的本发明化合物之前,将每个孔的细胞阻抗值归一化。为了说明目的,下面(表1)给出本发明的一些示例性化合物的EC50(nM)有效浓度值和相对于LPI活性的最大效应E max(%)的百分比:
表1由xCELLigence系统测量的本专利对GPR55的化合物实施例的激动作用。
上述值代表基于各重复两次的4次独立实验所计算的平均数及其95%置信区间。
实施例2、4、6-10和14的化合物是GPR55受体的部分激动剂。
GPR55激动剂活性。已经评估了本专利的示例性化合物抑制LPI介导的GPR55受体刺激的能力。为了说明目的,如下示出了在本发明的某些示例性化合物以1μM浓度存在的情况下的LPI EC50(nM)有效浓度值和相对于LPI活性的最大效应Emax(%)的百分比(表2)。
表2。由xCELLigence系统测量的本专利对GPR55的化合物实施例的激动作用。
上述值代表基于各重复两次的4次独立实验所计算的平均数及其95%置信区间。由于置信区间并未重叠,因此认为相对于LPI值具有显著差异。
实施例7-10的化合物是由LPI产生的GPR55激动剂作用的拮抗剂。
作为对照实验,发现本发明的示例性化合物对不过度表达GPR55受体的HEK293细胞没有作用。所述化合物均未显示细胞阻抗。
关于大麻素活性,本发明的示例性化合物均未结合大麻素受体CB1。就所有示例性化合物而言,在涉及CB2受体结合的情况下,仅3个实例具有小于微摩尔量级的值的亲和常数:实施例2(698±107nM)、实施例6(15.4±7.8nM)、实施例9(523±144nM)。
D.药代动力学特性:计算机模拟预测
通过使用Maestro(LLC,New York,USA)中实施的QikProp程序,通过计算机预测物理化学参数来确定本发明的示例性化合物的药代动力学概况。表3中示出的本专利的示例性化合物的数值遵循Lipinski规则。因此,它们被认为是可用作所述药物组合物的一部分的可接受的候选物。
表3由集成在Master(LLC,New York,USA)中的QikProp 3.5计算所得的物理化学参数[95%药物范围]。
a水中溶解度预测[-6.5/0.5];b血脑屏障通过预测[-3,0/1,2];cHERG K+通道(logIC50)[>-5];dCaco-2细胞表观渗透性(nm/s)[<25低,>500优良];e人口服胃肠道(GI)吸收度[<25%低]。
Claims (25)
1.如式(I)所示的化合物
或其互变异构体、其药学上可接受的盐或其溶剂化物;
其中:
-R1选自任选取代的芳基或-C(O)R3基团;其中,R3选自芳基、杂环基、C1-C6烷基、C3-C6环烷基或-(CH2)n-O-芳基,其中n是选自1、2、3或4的值,
-R2选自C1-C6亚烷基或-R4-C(O)-NH-R5-基团,R4和R5为相同或不同的C1-C6亚烷基。
2.如式(II)所示的化合物
或其互变异构体、其药学上可接受的盐或其溶剂化物;
其中R1和R2如权利要求1所定义。
3.如式(III)所示的化合物
或其互变异构体、其药学上可接受的盐或其溶剂化物;
其中R1和R2如权利要求1所定义。
4.根据前述权利要求任一项所述的化合物,其特征在于,R1为-C(O)R3基团。
5.根据权利要求4所述的化合物,其特征在于,R3为芳基。
6.根据权利要求5所述的化合物,其特征在于,R3为苯基。
7.根据前述权利要求任一项所述的化合物,其特征在于,R3为杂环基。
8.根据权利要求7所述的化合物,其特征在于,R3选自呋喃基、噻吩基或四氢呋喃基。
9.根据前述权利要求任一项所述的化合物,其特征在于,R3为环己基。
10.根据前述权利要求任一项所述的化合物,其特征在于,R3为C1-C4烷基。
11.根据权利要求1至10任一项所述的化合物,其特征在于,R2为C1-C4亚烷基。
12.根据权利要求11所述的化合物,其特征在于,R2为乙烯基。
13.根据权利要求1至12任一项所述的化合物,其特征在于,所述化合物选自:
-1-(2-(4-(2-呋喃甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-呋喃甲酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-苯甲酰基哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-苯甲酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(2-噻吩甲酰基)哌嗪基)乙基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2-噻吩甲酰基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(4-苯氧基乙酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2-四氢呋喃甲酰基)哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-环己基羰基-哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-新戊酰基哌嗪基)乙基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
14.根据述权利要求1至3中任一项所述的化合物,其特征在于,R1为任选取代的苯基。
15.根据权利要求14所述的化合物,其特征在于,R1是被C1-C4烷基或C1-C4烷氧基取代的苯基。
16.根据权利要求15所述的化合物,其特征在于,R1是被至少一个甲基或甲氧基取代的苯基。
17.根据权利要求14至16中任一项所述的化合物,其特征在于,R2为-R4-C(O)-NHR5-基团,R4和R5是相同或不同的C1-C4亚烷基。
18.根据权利要求17所述的化合物,其特征在于,R4和R5为亚甲基。
19.根据权利要求14至18中任一项所述的化合物,其特征在于,所述化合物选自:
-1-(2-(4-苯基哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(2-甲氧苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(2,3-二甲基苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-1-(2-(4-(4-甲氧基苯基)哌嗪基)乙酰氨基甲基)-1,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-苯基哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2-甲氧苯基)哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑;
-2-(2-(4-(2,3-二甲基苯基)哌嗪基)乙酰氨基甲基)-2,4-二氢-7-甲氧基-4,4-二甲基苯并吡喃[4,3-c]吡唑。
20.药物组合物,其包含如权利要求1至19中任一项所述的化合物。
21.根据权利要求20所述的药物组合物,其特征在于,其进一步包括另外的活性成分。
22.根据权利要求1至19中任一项所述的化合物用于制备药物的用途。
23.根据权利要求1至19中任一项所述的化合物在制备用于治疗和/或预防与GPR55受体有关的病症的药物中的用途。
24.根据权利要求23的用途,其特征在于,所述病症选自糖尿病、帕金森病、多发性硬化症、神经性疼痛、骨质疏松症、胆管癌、乳腺癌、卵巢癌和前列腺癌、成胶质细胞瘤和皮肤癌。
25.根据权利要求1至19中任一项所述的化合物用于制备与GPR55受体相关的生物学测定中的试剂的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201530608 | 2015-05-05 | ||
ES201530608A ES2593057B1 (es) | 2015-05-05 | 2015-05-05 | Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol |
PCT/ES2016/070314 WO2016177922A1 (es) | 2015-05-05 | 2016-04-27 | Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107735397A true CN107735397A (zh) | 2018-02-23 |
Family
ID=57217626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680039783.1A Pending CN107735397A (zh) | 2015-05-05 | 2016-04-27 | Gpr55受体活性选择性调节剂:苯并吡喃吡唑衍生物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10435412B2 (zh) |
EP (1) | EP3305794B1 (zh) |
JP (1) | JP2018515499A (zh) |
KR (1) | KR20180002717A (zh) |
CN (1) | CN107735397A (zh) |
AU (1) | AU2016257025A1 (zh) |
BR (1) | BR112017023834A2 (zh) |
CA (1) | CA2985021A1 (zh) |
ES (1) | ES2593057B1 (zh) |
IL (1) | IL255420A0 (zh) |
MX (1) | MX2017014145A (zh) |
RU (1) | RU2017138563A (zh) |
WO (1) | WO2016177922A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109420174B (zh) * | 2017-08-31 | 2021-07-13 | 清华大学 | Gpr18及其调节剂在防治免疫系统疾病中的应用 |
CN109420173B (zh) * | 2017-08-31 | 2021-07-13 | 清华大学 | Gpr55及其调节剂在防治免疫系统疾病中的应用 |
WO2023172415A1 (en) * | 2022-03-07 | 2023-09-14 | Firmenich Incorporated | Sweetener compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3624102A (en) * | 1969-05-21 | 1971-11-30 | Warner Lambert Co | Substituted benzopyranopyrazoles |
WO2009010824A1 (en) * | 2007-07-13 | 2009-01-22 | Glenmark Pharmaceuticals, S.A. | Dihydrochromenopyrazole derivatives as vanilloid receptor ligands |
WO2010109050A1 (es) * | 2009-03-24 | 2010-09-30 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromenopirazoles como ligandos de receptores de cannabinoides |
WO2014013117A1 (es) * | 2012-07-18 | 2014-01-23 | Consejo Superior De Investigaciones Científicas (Csic) | Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0010960D0 (en) | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Assay |
ES2304604T3 (es) * | 2003-02-18 | 2008-10-16 | Astrazeneca Ab | Ensayos de cribado para moduladores de gpr55 de tipo cannabinoide-ligando. |
EP2079736B1 (en) * | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
ES2548789B1 (es) | 2014-03-18 | 2016-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral |
-
2015
- 2015-05-05 ES ES201530608A patent/ES2593057B1/es active Active
-
2016
- 2016-04-27 WO PCT/ES2016/070314 patent/WO2016177922A1/es active Application Filing
- 2016-04-27 CA CA2985021A patent/CA2985021A1/en not_active Abandoned
- 2016-04-27 CN CN201680039783.1A patent/CN107735397A/zh active Pending
- 2016-04-27 AU AU2016257025A patent/AU2016257025A1/en not_active Abandoned
- 2016-04-27 EP EP16789355.1A patent/EP3305794B1/en active Active
- 2016-04-27 KR KR1020177034239A patent/KR20180002717A/ko unknown
- 2016-04-27 JP JP2017557942A patent/JP2018515499A/ja active Pending
- 2016-04-27 BR BR112017023834-9A patent/BR112017023834A2/pt not_active Application Discontinuation
- 2016-04-27 US US15/571,671 patent/US10435412B2/en active Active
- 2016-04-27 RU RU2017138563A patent/RU2017138563A/ru not_active Application Discontinuation
- 2016-04-27 MX MX2017014145A patent/MX2017014145A/es unknown
-
2017
- 2017-11-05 IL IL255420A patent/IL255420A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3624102A (en) * | 1969-05-21 | 1971-11-30 | Warner Lambert Co | Substituted benzopyranopyrazoles |
WO2009010824A1 (en) * | 2007-07-13 | 2009-01-22 | Glenmark Pharmaceuticals, S.A. | Dihydrochromenopyrazole derivatives as vanilloid receptor ligands |
WO2010109050A1 (es) * | 2009-03-24 | 2010-09-30 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromenopirazoles como ligandos de receptores de cannabinoides |
WO2014013117A1 (es) * | 2012-07-18 | 2014-01-23 | Consejo Superior De Investigaciones Científicas (Csic) | Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral |
Non-Patent Citations (1)
Title |
---|
PAULA MORALES,等: "Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Also Published As
Publication number | Publication date |
---|---|
EP3305794A1 (en) | 2018-04-11 |
ES2593057B1 (es) | 2017-09-12 |
EP3305794A4 (en) | 2018-11-07 |
IL255420A0 (en) | 2017-12-31 |
RU2017138563A3 (zh) | 2019-06-06 |
RU2017138563A (ru) | 2019-06-05 |
ES2593057A1 (es) | 2016-12-05 |
JP2018515499A (ja) | 2018-06-14 |
KR20180002717A (ko) | 2018-01-08 |
US20180201620A1 (en) | 2018-07-19 |
BR112017023834A2 (pt) | 2018-07-31 |
EP3305794B1 (en) | 2020-02-05 |
MX2017014145A (es) | 2018-06-20 |
WO2016177922A1 (es) | 2016-11-10 |
US10435412B2 (en) | 2019-10-08 |
AU2016257025A1 (en) | 2017-11-30 |
CA2985021A1 (en) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015250610B2 (en) | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | |
EP3156397B1 (en) | Nitrogen-containing heterocyclic compound | |
EP3144308B1 (en) | Nitrogen-containing heterocyclic compound | |
JP7135007B2 (ja) | 複素環化合物 | |
CN108368127B (zh) | 化合物及其作为ep4受体拮抗剂的用途 | |
JP7470058B2 (ja) | 複素環化合物 | |
JP5674483B2 (ja) | 新規なhsp90阻害性カルバゾール誘導体、同誘導体を含む組成物およびその使用 | |
KR101623357B1 (ko) | 5-ht6 길항제로서 아릴설포닐 피라졸린 카복스아미딘 유도체 | |
CN101547909A (zh) | 糖皮质激素模拟物、其制备方法、药物组合物及其用途 | |
CN114846012B (zh) | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 | |
US10106523B2 (en) | Amide compound | |
Kotsikorou et al. | The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB2 Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl) methyl]-N-[(1 S, 2 S, 4 R)-1, 3, 3-trimethylbicyclo [2.2. 1] hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528) | |
CN107735397A (zh) | Gpr55受体活性选择性调节剂:苯并吡喃吡唑衍生物 | |
JP2011500728A (ja) | 疾患の処置に有用なニコチン性アセチルコリン受容体の(1,4−ジアザ−ビシクロ[3.2.2]ノン−6−エン−4−イル)−ヘテロシクリル−メタノンリガンド | |
EP3643718B1 (en) | Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor. | |
CN112752760B (zh) | 杂环化合物 | |
JP7446232B2 (ja) | 縮合環化合物 | |
EP3858828A1 (en) | Heterocyclic compound | |
TW200804365A (en) | Selenophene compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180223 |
|
WD01 | Invention patent application deemed withdrawn after publication |